Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent ganglioside vaccine + OPT-821
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A combination investigational **vaccine-based immunotherapy** consisting of a trivalent ganglioside vaccine (containing GD2 and GD3 gangliosides stabilized as lactones, each conjugated to keyhole limpet hemocyanin/KLH) with **OPT-821**, a purified saponin adjuvant. OPT-821 is a semisynthetic QS-21 equivalent derived from *Quillaja saponaria* and serves to enhance the immune response to the ganglioside antigens. Developed mainly for high-risk neuroblastoma in remission, the vaccine is administered subcutaneously, often in combination with oral β-glucan as an additional immune stimulant. Trials report immunogenicity and tolerability, with antibody responses generated against GD2 and GD3, and some documentation of effects on minimal residual disease[1][2].
- Other names
- GD2/GD3/KLH vaccine + OPT-821ganglioside vaccine + OPT-821
02
Targets
GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on trivalent ganglioside vaccine + OPT-821.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent ganglioside vaccine + OPT-821.